Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Neuronal NF-κB ablation does not influence neuro-axonal degeneration in experimental autoimmune demyelination.
Intermittent feeding attenuates clinical course of experimental autoimmune encephalomyelitis in C57BL/6 mice.
Separated at birth? The functional and molecular divergence of OLIG1 and OLIG2.
Infectious causes of multiple sclerosis.
Teva to initiate third Phase III trial of oral laquinimod for the treatment of relapsing remitting multiple sclerosis
Solitary sclerosis: Progressive neurological deficit from a spatially isolated demyelinating lesion: A further report.
Placebo? no thanks, it might be bad for me!
MS related employment and disease modifying treatment in the German working population: 1994-2009.
Rush University Medical Center Sells AMPYRA® Royalty Rights to DRI Capital Managed Fund for Approximately $42 Million
Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis.
Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.
Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor.
Multiple sclerosis treatment: current best practice.
Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis.
Bayer Receives FDA Approval for BETACONNECT - First and Only Electronic Autoinjector in Relapsing-Remitting Multiple Sclerosis (RRMS) Treatment
The role of laquinimod in modulation of the immune response in relapsing-remitting multiple sclerosis: Lessons from gene expression signatures.
Multiparametric flow cytometric analysis of whole blood reveals changes in minor lymphocyte subpopulations of multiple sclerosis patients.
Myelin Basic Protein-Specific TCR/HLA-DRB5*01:01 Transgenic Mice Support the Etiologic Role of DRB5*01:01 in Multiple Sclerosis.
High-dose cyclophosphamide in multiple sclerosis patients undergoing autologous stem cell transplantation.
Identification of protein networks involved in the disease course of experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis.
JC-virus seroconversion in multiple sclerosis patients receiving natalizumab.
Vitamin D: a natural inhibitor of multiple sclerosis.
CD4 cell response to interval therapy with natalizumab.
A pooled analysis of two phase 3 clinical trials of dalfampridine in patients with multiple sclerosis.
Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter.

Pages